

Tarsus Pharmaceuticals Announces Upsized Underwritten Public Offering

Client News

May 3, 2022

Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its **upsized underwritten public offering of 5,600,000 shares of common stock** at a public offering price of \$13.50 per share which represents \$75.6 million of common stock. The company focuses on advancing its pipeline to address several diseases with high unmet needs across a range of therapeutic categories, including eye care.

The Gunderson deal team was co-led by Ryan Gunderson and Ilan Lovinsky and included Leanne Gould and Bettina Tiangco.

Related People



Ryan J. Gunderson

PARTNER

P +1 858 436 8046

Ilan Lovinsky
PARTNER EMERITUS
P +1 858 436 8000



Bettina A. Tiangco
ASSOCIATE
P +1 858 436 8016

Related Services

Public Companies

Public Companies/Public Offerings

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnicor Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

ChainGuard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)